EU Commission Approves LORVIQUA® (LORLATINIB) For Adult Patients With Non-Small Cell Lung Cancer

The FINANCIAL -- Pfizer Inc. these days announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA® (lorlatinib, available in the U.S., Canada and Japan under the brand name LORBRENA®), as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as